Description: Emmaus Life Sciences, Inc. engages in the discovery, development, and commercialization of treatments and therapies primarily for rare and orphan diseases in the United States and internationally. It provides Endari, which is L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older; NutreStore L-glutamine powder; and AminoPure, a nutritional supplement. The company also develops therapeutic products based on cell sheet technology for the treatment of corneal diseases. In addition, it focuses on developing pharmaceutical-grade L-glutamine oral powder for diverticulosis. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. Emmaus Life Sciences, Inc. was founded in 2000 and is headquartered in Torrance, California.
Home Page: www.emmausmedical.com
21250 Hawthorne Boulevard
Torrance,
CA
90503
United States
Phone:
310 214 0065
Officers
| Name | Title |
|---|---|
| Dr. Yutaka Niihara M.D., M.P.H, M.P.H. | Chairman & CEO |
| Mr. Willis C. Lee M.S. | Vice Chairman & COO |
| Mr. Yasushi Nagasaki CPA, CPA | Chief Financial Officer |
| Mr. George Sekulich | Sr. VP of Global Commercialization & Chief Information Officer |
| Mr. Dale E. Short J.D. | Gen. Counsel |
| Dr. Charles W. Stark Pharm.D, Pharm.D. | Sr. VP of Medical Affairs, Clinical, Regulatory |
| Mr. Kurt H. Kruger M.B.A., M.S. | Consultant |
| Mr. S. Steven Lee | Independent Consultant |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 1.0565 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 58 |